Movement Alert｜Halozyme Therapeutics Intraday Rise 5.23% in Regular Trading, EU injunction against Merck's Keytruda SC supports patent outlook

Market Focus10-14 21:45

On October 14, Halozyme Therapeutics rose 5.23% in Regular Trading, trading at $115.225 per share, with turnover of $28.5878 million.

The move was supported by renewed attention to a court ruling that granted Halozyme an injunction barring manufacture, marketing, or import of Merck's Keytruda SC in multiple European markets after finding infringement of one of Halozyme's MDASE patents.

The ruling covers Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands, and also rejected arguments that the patent was invalid. The decision does not affect the intravenous version of Keytruda, which remains available to patients. The development strengthens Halozyme Therapeutics' legal position around its drug-delivery intellectual property and reinforces expectations for the durability of its licensing and royalty model.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment